Onconetix Inc. is a cutting-edge biotechnology firm committed to revolutionizing cancer care with its innovative diagnostic and therapeutic solutions. Utilizing a proprietary technology platform, the company specializes in early detection and personalized treatment for a range of malignancies, addressing key unmet needs in the oncology space. With a strong and diverse product pipeline, Onconetix is well-positioned to capitalize on the increasing demand for effective cancer therapies, aiming to significantly improve patient outcomes through its advanced research and development efforts in this dynamic and rapidly advancing field.
| Revenue (TTM) | 645,820 |
| Gross Profit (TTM) | 519,230 |
| EBITDA | $-7.67M |
| Operating Margin | -13112.00% |
| Return on Equity | -105.20% |
| Return on Assets | -27.00% |
| Revenue/Share (TTM) | $1.09 |
| Book Value | $3.55 |
| Price-to-Book | 0.22 |
| Price-to-Sales (TTM) | 6.18 |
| EV/Revenue | 0.204 |
| EV/EBITDA | -0.47 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -83.90% |
| Shares Outstanding | $4.38M |
| Float | $3.95M |
| % Insiders | 0.15% |
| % Institutions | 6.61% |
Volatility is currently expanding
Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition
Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition
Pilot Tests Humanoid Robots as Presenters, Hosts, and Brand Ambassadors Before Live Audiences, Extending Robot Capabilities Beyond One-on-One Interaction into Dynamic, Audience-Facing Environments; Onconetix Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp.
Entertainment Industry Agreement Reflects Real-World Adoption of Humanoid Robotics Technology Across Education, Healthcare, Hospitality, and Customer Engagement; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC (“Realbotix”), the target of Onconetix's previously announced pending acquisition. Realbotix has entered into an agreement with a recognized streaming platform to feature one of its humanoid robots as a robotic character in an upcoming episode of a popular Emmy-awarded television series.
Proteomedix Co-Founder and Proclarix® Co-Developer Returns to Company's Board; Thomas Meier, PhD Re-Elected as Chairman at Annual General Meeting CINCINNATI, Ohio , Aug. 05, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) today announced that its fully-owned Swiss subsidiary, Proteomedix AG (“PMX”), has appointed Ralph Schiess, PhD to the PMX Board of Directors. The appointment was approved at the PMX Annual General Meeting of Shareholders held on June 22, 2026, at which Thomas Meier, PhD was also re-elected to serve an additional one-year term as Chairman of the Board.
Realbotix Robots and AI to Deploy in Evidence-Based Pilot Designed to Improve Wellbeing and Address Loneliness Among Older Adults in UK Care Settings; Realbotix Becomes Accredited Supplier on Bloom's Public Sector Marketplace; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, July 07, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC (“Realbotix”), the target of Onconetix's previously announced pending acquisition. Realbotix has announced a partnership with Bloom Procurement Services (“Bloom”), a UK public sector procurement specialist, to launch a pilot program deploying socially assistive humanoid robots to combat loneliness and improve wellbeing among elderly residents in Northeast England.
Salamanca City Central School District on Seneca Nation Reservation to Deploy Optio and Realbotix M-Series Humanoid Robot; Pilot to Expand to Approximately 500 High School Students in Fall 2026; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp.
CINCINNATI, Ohio, May 19, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for oncology, today announced that its Board of Directors (the “Board of Directors” or “Board”) has approved a 1-for-10 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on May 21, 2026.
LAS VEGAS--(BUSINESS WIRE)--Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Parent Company”), a leading AI humanoid robot manufacturer for social tasks, is pleased to provide an update on its previously announced transaction to list Realbotix LLC (“RealLLC” or the “Subsidiary”), a wholly owned subsidiary of Realbotix, on the Nasdaq Capital Market via a reverse takeover transaction with Onconetix, Inc. (NASDAQ: ONCO) (“ONCO”). The proposed transaction will res.
New Clinical Data Reinforce Proclarix® Performance in Reducing Overdiagnosis and Unnecessary Biopsies; Multi-Center PRIME Study Initiated in Collaboration with Labcorp; European Commercial Expansion Advances
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ONCO and any ticker you trade — then tracks every position and per-strategy win rate.
